Home > Pulmonology > ERS 2022 > Icenticaftor achieves results on top of triple inhalation therapy in COPD

Icenticaftor achieves results on top of triple inhalation therapy in COPD

Presented By
Prof. Frits Franssen, Maastricht University, the Netherlands
Conference
ERS 2022
After 24 weeks, the use of icenticaftor on top of triple inhalation therapy resulted in a clear dose-response on 5 endpoints in patients with COPD and chronic bronchitis. The 300 mg, twice daily dose of the drug showed an encouraging benefit-risk profile and should be investigated in further trials. A phase 2b trial (NCT02449018), conducted by Prof. Frits Franssen (Maastricht University, the Netherlands) and co-investigators, assessed the dose-response relationship of icenticaftor on top of a triple therapy of long-acting beta-agonists (LABA), long-acting muscarinic antagonists (LAMA), and inhaled corticosteroids (ICS) in patients with COPD (GOLD 2 & 3) and chronic bronchitis (n=974). The trial included 5 incenticaftor arms, with doses ranging from 25 mg, twice daily, to 450 mg, twice daily, and a placebo arm. The primary endpoint was the change in trough force...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on